Zai Lab (NASDAQ:ZLAB) Issues Earnings Results, Beats Estimates By $0.18 EPS

Zai Lab (NASDAQ:ZLAB) posted its earnings results on Thursday. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.18, FiscalAI reports. Zai Lab had a negative net margin of 39.29% and a negative return on equity of 24.32%. The business had revenue of $106.31 million for the quarter, compared to the consensus estimate of $103.87 million.

Here are the key takeaways from Zai Lab’s conference call:

• Positive Sentiment: Zai Lab reported second-quarter net product revenue of $105.8 million, up 11% sequentially, while maintaining a commercially profitable business. Management expects KarXT, potential NRDL inclusions, and continued demand for key brands to support meaningful growth in 2027.
• Positive Sentiment: The DLL3 ADC zoci is advancing rapidly, with a global Phase III second-line small-cell lung cancer trial expected to complete enrollment in the first half of 2027 and a potential U.S. accelerated-approval submission later that year. The company also plans a first-line, chemo-sparing Phase III combination study and expects three registrational programs by year-end.
• Positive Sentiment: ZL-1503, a long-acting IL-13/IL-31 bispecific for atopic dermatitis, is expected to generate initial human pharmacokinetic, pharmacodynamic, safety, and immunogenicity data in the second half of 2026. Zai believes its potential for durable itch reduction, skin clearance, and less frequent dosing could differentiate it in a competitive market.
• Negative Sentiment: Management did not reaffirm its prior goal of reaching overall profitability by the end of 2025, instead indicating that profitability will develop over time as revenue grows and global assets advance. Continued investment in multiple global programs means operating expenses are expected to remain broadly stable through the rest of 2026.
• Neutral Sentiment: The company ended the quarter with $717.5 million in cash and is prioritizing spending on its highest-value programs while streamlining operations and expanding AI use across functions. Additional pipeline catalysts include initial ZL-6201 data expected in the first half of 2027 and an IND filing for the MUC17 T-cell engager ZL-1311 by year-end.

Zai Lab Trading Up 13.7%

NASDAQ:ZLAB traded up $2.51 on Thursday, reaching $20.88. 1,388,022 shares of the stock traded hands, compared to its average volume of 799,173. Zai Lab has a 1-year low of $15.96 and a 1-year high of $36.77. The company’s 50 day moving average is $18.59 and its 200-day moving average is $19.20. The firm has a market capitalization of $2.38 billion, a price-to-earnings ratio of -12.89 and a beta of 0.78.

Insider Transactions at Zai Lab

In other news, CEO Ying Du sold 50,000 shares of the company’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $20.09, for a total value of $1,004,500.00. Following the sale, the chief executive officer directly owned 1,122,626 shares of the company’s stock, valued at approximately $22,553,556.34. This represents a 4.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director William Lis sold 7,040 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $18.09, for a total transaction of $127,353.60. Following the sale, the director owned 50,437 shares of the company’s stock, valued at approximately $912,405.33. This trade represents a 12.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 90,873 shares of company stock worth $1,730,096. Company insiders own 4.88% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada grew its stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,771 shares of the company’s stock after acquiring an additional 9,390 shares during the period. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on ZLAB shares. Wall Street Zen downgraded shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Citigroup lowered their target price on Zai Lab from $47.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 8th. Finally, Zacks Research raised Zai Lab from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Zai Lab currently has an average rating of “Moderate Buy” and an average price target of $40.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.